Why Scale Matters in Silicone Scar Therapy
In my practice, the most commonly undertreated scars are not the long ones. They are the small ones: the 8mm punch biopsy site on the upper back, the mole removal mark on the cheek, the acne cyst excision on the chest, the piercing scar that never fully flattened. Patients assume that because a scar is small, it requires less intervention. The clinical reality is the opposite. A discrete pinpoint scar in a high skin tension zone is at significant risk for hypertrophic response, and the window for preventing that outcome with silicone therapy is the same as it is for any other scar. What changes is the format.
A full silicone sheet or a long strip applied to a scar less than one inch in diameter does not provide better coverage. It provides inconsistent coverage, with the sheet bridging over the scar surface rather than maintaining direct contact across it, adhesive edges that lift because the surrounding skin is moving more than the sheet can accommodate, and a silicone footprint that extends far beyond the tissue that needs treatment. For isolated pinpoint scars, the 1-inch pre-shaped silicone dot is not a convenience product. It is the clinically correct format.
Quick Answer
Product: Silagen Clear Silicone Dots, 1 inch diameter (Biodermis) Indicated for: Post-biopsy scars, mole removal scars, acne cyst excision scars, piercing scars, and small surgical excision marks where the scar diameter is one inch or less Start date: Two weeks after wound closure once the skin is fully epithelialized, with no open areas, crusting, or active inflammation present across the full scar perimeter Protocol duration: Twice daily, minimum 8 to 12 weeks; up to 6 months for patients with hypertrophic scar history or scars located in high skin tension zones including the chest, shoulders, and upper back Format: 1 inch pre-shaped medical-grade silicone dot, clear, reusable
Why Pinpoint Scars Develop Hypertrophic Responses and What Silicone Does About It
Scar maturation progresses through three phases: inflammatory, proliferative, and remodeling. The inflammatory phase begins immediately after wounding and clears within the first one to two weeks as the immune response resolves. The proliferative phase follows, during which fibroblasts populate the wound site and begin synthesizing collagen to reconstruct the tissue architecture. It is during this phase that the therapeutic window for silicone intervention opens. If fibroblast activity during the proliferative phase is allowed to run unchecked, particularly in anatomical zones with elevated dermal tension, the result is excess collagen deposition and the raised, firm, erythematous scar profile characteristic of hypertrophic scarring. Silicone therapy initiated in the proliferative phase and sustained through the remodeling phase intercepts that process before it becomes established.
The mechanism is straightforward. Scar tissue loses water across its surface at a rate significantly higher than intact skin because the disrupted epithelial architecture cannot regulate transepidermal water loss, TEWL, the way normal skin does. That chronic water loss creates a dry microenvironment that keeps fibroblasts in a hyperactivated state, continuing to produce collagen beyond what the repair process requires. When a silicone dot is placed directly over the scar, it forms a semi-occlusive contact layer that restores moisture balance at the scar surface. Fibroblast activity normalizes in response. The collagen profile shifts from the disorganized type III collagen characteristic of active hypertrophic scarring toward the organized type I collagen of mature, normal skin. The scar flattens, softens, and loses its erythema progressively over the treatment period.
For pinpoint scars, this mechanism is most effective when the silicone is in direct, continuous contact with the full scar surface. That is precisely what the 1-inch dot format achieves and what a full sheet format does not, on a scar this small.
Mustoe et al. (2002) established silicone sheeting as the evidence-supported standard for non-invasive hypertrophic scar management. Gold et al. (2001) confirmed measurable outcome improvements in scar height, pliability, and vascularity across controlled silicone product use. Juckett and Hartman-Adams (2009) further support early prophylactic silicone initiation as the standard of care for patients at elevated hypertrophic risk.
Fitzpatrick Skin Types IV Through VI and the PIH Risk Specific to Pinpoint Scars
Post-inflammatory hyperpigmentation is a distinct concern for patients with Fitzpatrick skin types IV through VI, and it presents differently on pinpoint scars than on longer incision lines. On a small isolated scar, the pigmentary response to inflammation is concentrated in a discrete spot. Because the affected area is small, patients frequently delay seeking treatment, interpreting the pigment change as temporary. In many cases it is not, and by the time a patient presents for evaluation the PIH is established and requires more intervention than early silicone therapy would have required to prevent it.
For my patients in Fitzpatrick types IV through VI with post-biopsy, post-excision, or post-acne cyst scars, I initiate silicone dot therapy prophylactically as soon as the wound is fully epithelialized. The anti-inflammatory effect of the semi-occlusive microenvironment silicone creates reduces the local inflammatory burden that drives melanocyte overactivation and subsequent hyperpigmentation. Early initiation is not optional for this patient group. It is the standard I apply.
Hypertrophic Risk at High-Tension Anatomical Sites
Not all pinpoint scars carry the same hypertrophic risk. Scars located on the chest, shoulders, and upper back sit in zones where dermal tension is persistently elevated by normal movement and posture. A post-biopsy scar on the mid-chest and a post-biopsy scar on the forearm are not equivalent in their healing trajectory. The chest scar is under tension with every breath. That mechanical stress activates fibroblasts continuously during the proliferative phase, producing the dense, raised collagen that defines a hypertrophic scar.
Post-acne cyst excision scars on the upper back and shoulders fall into the same risk category. The combination of follicular disruption, high dermal tension, and the inflammatory history of the cyst itself makes these among the most hypertrophic-prone presentations I manage in my practice. For these patients I extend the silicone dot protocol to six months as standard, not as an extended option. Hypertrophic response at these locations, once established, requires substantially more intervention to reverse than the prevention protocol costs.
The Protocol I Use for Silicone Dot Therapy
Begin silicone dot therapy two weeks after wound closure once every part of the scar perimeter is fully epithelialized. No open areas, crusting, or wound separation should be present before starting. For patients who experienced delayed closure at any point along the scar edge, that area must be fully healed before the dot is applied.
Clean the scar area thoroughly and allow it to dry completely before each application. Center the dot directly over the scar and press flat from the center outward to ensure full contact across the entire scar surface. The goal is complete silicone-to-scar contact with no air pockets or lifted edges. On convex surfaces such as the upper back or shoulder, pressing from the center outward is particularly important because edge lift on curved surfaces begins at the perimeter and progresses inward if adhesion is not established correctly at application.
Wear the dot for a minimum of 20 hours per day. Remove it for cleaning, wash gently with mild soap and water, rinse thoroughly, and allow it to air dry on a clean flat surface before reapplication. Do not store the dot folded. Apply twice daily if the wear time cannot be sustained as a single continuous period, though continuous wear is preferable for maintaining the semi-occlusive microenvironment consistently.
Silagen Clear Silicone Dots are available at The Skin Spot as part of my curated scar care collection. Every Silagen product I carry is physician-verified and guaranteed authentic.
Silicone Dot vs. Silicone Gel: The Clinical Distinction for Small Isolated Scars
Both the silicone dot and Silagen Scar Gel reduce TEWL and regulate fibroblast activity through the same semi-occlusive mechanism. The clinical difference is contact pressure and surface geometry.
A silicone dot applies localized mechanical pressure directly over the scar in addition to its semi-occlusive effect. On a discrete circular scar, that pressure is distributed evenly across the full scar surface, which enhances the flattening effect beyond what TEWL reduction alone produces. Gel forms a conforming film and excels on irregular, contoured, or facial scars where a rigid dot format cannot follow the surface changes. On a flat or minimally contoured pinpoint scar, the dot provides more stable and consistent contact than a gel film.
The format decision for small scars comes down to surface geometry. If the scar is on a surface a 1-inch dot can lie flat against, the dot is the correct format. If the scar sits across a contour change, on the nasal tip, along the ear, or in a fold, gel is more appropriate. As with all formats in this series: silicone dot and silicone gel must not be used simultaneously on the same scar area. Combining them disrupts the adhesion mechanism of the dot and does not produce additive benefit.
What to Expect Week by Week
Weeks 1 to 2: The primary objective is establishing consistent contact across the full scar surface and confirming skin tolerance. Some patients with sensitive skin notice mild adhesive awareness during the first few days. This resolves as the skin adjusts. No visible scar change is expected at this stage.
Weeks 3 to 6: Erythema at the scar site typically begins to diminish during this window. The scar surface frequently feels softer to the touch before visible flattening becomes apparent, which reflects early collagen remodeling at the dermal level. Patients with scars on the chest or shoulders may see slower erythema reduction in this window due to the persistent mechanical tension at those sites.
Weeks 7 to 12: Scar height and firmness decrease measurably in patients who have maintained twice-daily protocol compliance. Pliability improves. For post-acne cyst scars with an established hypertrophic profile at baseline, this period shows the most visible structural change.
Months 3 to 6: Patients with hypertrophic-prone scars or scars in high skin tension anatomical zones continue to remodel during this extended period. Stopping the protocol at 12 weeks because the scar appears improved is the most common error I see. The remodeling phase remains active and responsive to silicone therapy well beyond the 12-week mark for this patient group.
Frequently Asked Questions
When can I start silicone dot therapy after a biopsy or mole removal?
I start patients on silicone dot therapy two weeks after the procedure once the skin is fully epithelialized across the entire scar perimeter. For a standard punch biopsy or shave removal, that timeline is typically consistent. For excisions closed with sutures, I wait until suture removal is complete and the closure line is fully healed with no crusting or wound edge separation present. Any area that has not closed must be excluded from treatment until it does.
What is the difference between a silicone dot and silicone gel for a small scar?
The mechanism is the same: both reduce TEWL and regulate fibroblast activity through a semi-occlusive silicone layer. The difference is contact pressure and surface conformance. The dot applies localized mechanical pressure directly over a discrete circular scar, which contributes to flattening beyond the TEWL effect alone. Gel conforms to irregular surfaces and contours where a rigid dot cannot lie flat. For a small, flat, isolated scar on a relatively even skin surface, the dot is the more effective format. For a small scar on a curved or contoured surface, gel is the better choice.
Can I wear the silicone dot under makeup?
Yes. The dot is clear and sits flat against the skin. Once applied correctly, standard foundation and concealer can be worn over it without disrupting adhesion. I tell patients to apply the dot first on clean dry skin, allow a moment for it to settle into full contact, and then apply makeup over it in the normal order. Remove the dot at the end of the day, clean it, and reapply after the evening skincare routine on clean dry skin.
Can I trim the dot if it extends slightly beyond the scar border?
Yes, if a small portion of the dot edge extends onto healthy skin and is causing edge lift or skin irritation, it can be trimmed with clean scissors before application. Trim conservatively, removing only what is necessary. Do not trim while the dot is adhered to the skin, and do not reduce the dot size to the point where it no longer fully covers the scar surface. Full scar coverage is the clinical objective.
How long does each dot last with daily use?
With correct cleaning and storage, a single dot typically maintains effective adhesion for one to two weeks of twice-daily use. Adhesion declines gradually with each wash cycle. When the dot no longer lies flat against the scar surface without repositioning, it should be replaced. Patients should have enough dots on hand to complete the full protocol duration without interruption, since gaps in coverage interrupt the semi-occlusive microenvironment the therapy depends on.
References
Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560-571.
Gold MH, Foster TD, Adair MA, Burlison K, Lewis T. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting. Dermatol Surg. 2001;27(7):641-644.
Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80(3):253-260.
Ready to begin a targeted silicone protocol for a pinpoint scar? Shop Silagen Clear Silicone Dots at The Skin Spot or explore the full Silagen scar care collection for gel, strip, and sheet formats suited to larger or differently shaped scars. For guidance on which format is right for your specific scar, reach out to our team [contact link pending verification].
About the Author
Dr. Sheila Nazarian is a board-certified plastic and reconstructive surgeon based in Beverly Hills, California, and the founder of Nazarian Plastic Surgery, Spa26, and The Skin Spot. She serves as Assistant Professor in the Division of Plastic Surgery at the University of Southern California and is the star of the Emmy-nominated Netflix series Skin Decision: Before and After. Small excision scar management, post-biopsy scar therapy, and silicone protocol selection for isolated pinpoint scars are a routine component of her post-procedure care plans for both surgical and in-office patients. Learn more about Dr. Nazarian at The Skin Spot.